Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission
Dyne Therapeutics, Inc DYN
$17.37
▲ +0.00%
(+$0.00)
Open
$17.21
Prev Close
$17.37
Day Range
$17.15 – $17.97
52W Range
$8.06 – $25.00
Market Cap
$2.87B
Beta
1.08
EPS (TTM)
$-3.54
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-09-17 |
| Shares Out. | 165,310,000 |
| Website | dyne-tx.com/ ↗ |
| Phone | 18009279800 |
Dyne Therapeutics, Inc is a publicly traded company under the ticker symbol DYN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-05-01)
📰 Latest News for DYN
Dyne Therapeutics Initiates Phase 3 FORZETTO Trial Of Zeleciment Rostudirsen In Individuals With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $33
Bernstein Maintains Market Perform on Dyne Therapeutics, Raises Price Target to $24
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Dyne Therapeutics Q1 EPS $(0.73) Beats $(0.78) Estimate
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights